10,11 $
5,07 % heute
Nasdaq, 7. Oktober, 18:47 Uhr
ISIN
US4884451075
Symbol
ZVRA
Berichte

KemPharm, Inc. Aktie News

Neutral
GlobeNewsWire
etwa 19 Stunden alt
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company's common stock (the “Inducement Awards”) to two new employees pursuant t...
Neutral
GlobeNewsWire
19 Tage alt
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients
Neutral
GlobeNewsWire
etwa ein Monat alt
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression
Neutral
GlobeNewsWire
etwa ein Monat alt
CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 2-...
Neutral
GlobeNewsWire
etwa ein Monat alt
CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate in the following September events:
Negativ
Investors Business Daily
etwa 2 Monate alt
Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.
Neutral
Seeking Alpha
etwa 2 Monate alt
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adrian Quartel - Chief Medical Officer Joshua M. Schafer - Chief Commercial Officer Neil F.
Neutral
GlobeNewsWire
etwa 2 Monate alt
Q2 2025 net revenue of $25.9 million , driven by product net revenue of $21.8 million

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen